By Denny Jacob
AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint.
Shares were recently trading around $17. The stock is down about 44% over the last year.
AnaptysBio said the phase 2b study of rosnilimab in patients with moderate-to-severe rheumatoid arthritis on background conventional disease-modifying antirheumatic drugs met its main goal of lowering disease activity at week 12 in all three doses of the drug.
The clinical stage biotechnology company said rosnilimab achieved statistical significance in at least one dose and numerical superiority at all doses on key secondary endpoints at week 12, even though higher than typical placebo rates were observed.
AnaptysBio added that data across all doses showed immunological impact with robust on-target pharmacological activity in patients under treatment that was not observed for those on placebo.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 12, 2025 08:21 ET (13:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。